| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Stephanie Lovell is Director at TMDX, with reported holdings spanning 2 companies. Stephanie Lovell's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $398K at current prices.
Our model assigns Stephanie Lovell a below-average insider score of 30/100, based on 3 past trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -18.6%.
Stephanie Lovell's largest disclosed position is in TMDX as Director, worth about $390K. The TMDX filings lean toward selling, a net 11,750 shares.
Stephanie Lovell has 14 Form 4 filings on record from April 2019 to May 2026, across 2 companies: Director at TransMedics Group (TMDX), 2021–2026; Director at Cyclerion Therapeutics (CYCN), 2019–2022.
The 21 reported transactions were 9 option or other derivative awards, 5 stock awards, 4 open-market sales and 3 option exercises.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $799K.
The largest open-market sale was 10,557 shares of TMDX at an average $58.80 on November 23, 2022, about $621K. Twelve months later TMDX was up 18%.